Cite
HARVARD Citation
Richardson, P. et al. (2021). Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of clinical oncology. 39 (22), pp. 2430-2442. [Online].